IP Library Granted Patent US 7,846,726
Granted Patent B2
US 7,846,726 · App. 10/366,032 · Granted Dec 7, 2010

Human fetal bladder-derived epithelial cells

Assignee: Raven biotechnologies, inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,846,726
App. No.
10/366,032
Granted
Dec 7, 2010
Kind
B2
Abstract

This invention discloses a substantially pure population of human urinary bladder-derived epithelial cells and methods of isolating and culturing the urinary bladder-derived epithelial cells. In addition, several uses of human urinary bladder-derived epithelial cells and cells differentiating therefrom are disclosed herein.

Claims (13)

1. A method of isolating a substantially pure population of human fetal urinary bladder epithelial cells having a capacity to differentiate into either differentiated bladder or prostate epithelium, wherein said cells are positive for molecular marker H19 imprinted gene mRNA and lacking alpha-actin expression, comprising:

(a) microdissecting human fetal urinary bladder tissue at gestational age from 14-21 weeks;

(b) placing the microdissected human fetal urinary bladder tissue in a serum-free nutrient medium under culture conditions sufficient to sustain fetal urinary bladder epithelial cells wherein the serum-free medium contains nutrients comprising insulin, transferrin, α-tocopherol, and aprotinin;

(c) maintaining suitable culture conditions sufficient to allow the migration of fetal urinary bladder epithelial cells from the human fetal urinary bladder tissue into the serum-free nutrient medium; and

(d) maintaining suitable culture conditions to obtain a substantially pure population of fetal urinary bladder epithelial cells having a capacity to differentiate into differentiated bladder or prostate epithelium.

2. The method of claim 1 , wherein said serum-free nutrient medium further comprises progesterone, keratinocyte growth factor (KGF) and heregulin (HRG).

3. A substantially pure isolated population of human fetal urinary bladder epithelial cells having a capacity to differentiate into either differentiated bladder or prostate epithelium, wherein said cells are positive for molecular marker H19 imprinted gene mRNA and lacking alpha-actin expression, produced by the process comprising:

(a) microdissecting human fetal urinary bladder tissue at gestational age from 14-21 weeks;

(b) placing the microdissected human fetal urinary bladder tissue in a serum-free nutrient medium under culture conditions sufficient to sustain fetal urinary bladder epithelial cells wherein the serum-free medium contains nutrients comprising insulin, transferrin, α-tocopherol, and aprotinin;

(c) maintaining suitable culture conditions sufficient to allow the migration of fetal urinary bladder epithelial cells from the human fetal urinary bladder tissue into the serum-free nutrient medium; and

(d) maintaining suitable culture conditions to obtain a substantially pure population of urinary bladder epithelial cells.

4. The population of cells of claim 3 , wherein the serum-free nutrient medium used in said process further comprises progesterone, keratinocyte growth factor (KGF) and heregulin (HRG).

5. A substantially pure isolated population of human fetal urinary bladder epithelial cells established from human fetal bladder tissue at gestational age from 14-21 weeks wherein said cells have a capacity to differentiate into either differentiated bladder or prostate epithelium and wherein said cells are positive for molecular marker H19 imprinted gene mRNA and lacking alpha-actin expression.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2014
From: MACROGENICS WEST, INC.
To: MACROGENICS, INC.
Reel/Frame 034630/0402 →
SECURITY AGREEMENT Recorded Jan 12, 2011
From: DIADEXUS, INC. (FORMERLY VAXGEN, INC.)
To: RAVEN BIOTECHNOLOGIES, INC.
Reel/Frame 025622/0237 →
SECURITY AGREEMENT Recorded Jun 13, 2008
From: RAVEN BIOTECHNOLOGIES, INC.
To: VAXGEN, INC.
Reel/Frame 021096/0008 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2004
From: LI, RONGHAO; PAN, ZHUANGYU
To: RAVEN BIOTECHNOLOGIES, INC.
Reel/Frame 014485/0769 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2003
From: LI, RONHAO; PAN, ZHUANGYU
To: RAVEN BIOTECHNOLOGIES, INC.
Reel/Frame 014206/0707 →
Continuity (2)
Provisional Application 6035703500 · Feb 12, 2002
Related Publication 20030211090A1 · Nov 13, 2003